AlphaCrest Capital Management’s Amedisys AMED Stock Holding History

AlphaCrest Capital Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,484	Closed	-$1.5M	–	65
2022 Q3	$1.5M	Buy	15,484 +9,628	+164%	+$1.15M	0.09%	364
2022 Q2	$616K	Buy	+5,856	New	+$748K	0.03%	882
2021 Q4	–	Sell	-11,233	Closed	-$1.68M	–	1363
2021 Q3	$1.68M	Buy	11,233 +1,017	+10%	+$211K	0.09%	380
2021 Q2	$2.5M	Buy	+10,216	New	+$2.68M	0.11%	285
2020 Q4	–	Sell	-1,887	Closed	-$446K	–	1107
2020 Q3	$446K	Buy	+1,887	New	+$429K	0.05%	646
2020 Q1	–	Sell	-1,437	Closed	-$240K	–	1006
2019 Q4	$240K	Sell	1,437 -482	-25%	-$71.7K	0.02%	1156
2019 Q3	$251K	Buy	+1,919	New	+$250K	0.02%	1151
2019 Q2	–	Sell	-2,010	Closed	-$248K	–	1006
2019 Q1	$248K	Buy	+2,010	New	+$252K	0.04%	718

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AlphaCrest Capital Management's AMED Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Amedisys (AMED) in Q4 2022, closing a stake of 15,484 shares — an estimated $1.5M sold.

AlphaCrest Capital Management first reported a position in AMED in Q1 2019 and held it in 8 quarters. The position peaked at $2.5M in Q2 2021. 278 funds tracked by Wall St. Rank hold AMED as of Q4 2022.

AlphaCrest Capital Management reported no remaining Amedisys position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 15,484 Amedisys shares in Q4 2022, an estimated $1.5M.
AlphaCrest Capital Management first reported a position in Amedisys in Q1 2019 and held it in 8 quarters.
AlphaCrest Capital Management's Amedisys position peaked at $2.5M in Q2 2021.
278 funds tracked by Wall St. Rank held Amedisys as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.